TVB-2640 is currently being explored in phase 1 clinical trials for the treatment of colon cancers and has recently entered phase 2 clinical trials for the treatment of Her2+ breast cancers [6]. This evidence concerns the gene ERBB2 and malignant colon neoplasm.